BioBuzzJlabsDozens of life sciences startups and early-stage company companies are honing their pitch decks and looking to head to New York, the center of the financial world, for a one-day investor and partnering event in hopes of securing financial partnerships.

In May, Johnson & Johnson – JLABS will hold its third annual Investor & Partnering Day in New York City at the New York Genome Center, a non-profit hub for collaborative genomic research and the home of JLABS @ NYC. The partnering day offers participating companies multiple meetings with investor organizations to highlight their science & technology, expand their investor network, and potentially securing funding to support ongoing and future operations.

“Raising capital is typically a challenge for early life science biotechs, and connecting with strategically aligned investors at the right time is essential,” said Sally Allain, Head of JLABS @ Washington, DC. “These events take some of the stress off of the companies, as we’re able to make introductions, curate a day of meetings with investors who are within our network, and support companies in shaping their pitch deck and story, all which can lead to valuable feedback or even funding.”

Past participating investors include Johnson & Johnson – JJDC, JP Morgan, Silicon Valley Bank, 5AM Ventures, Sands Capital, Anzu Partners, Epidarex Capital, Noblis Ventures, and others. Additionally, participants will benefit from experts, such as those from J&J JJDC, Inc., the investment arm of the life sciences giant. By moving it to New York City, the event will raise the profile for JLABS portfolio companies and expand its reach to new life science investors.

For some companies, this will be a first-time event where the leadership will share their company vision and data with potential partners. Other companies will look to make a return trip to the event. Previous participating companies include LifeBridge Innovations and Polaris Genomics plan to attend the JLABS event in New York City this year, each hoping to gain support for a Series financial raise.

Click here to read more via BioBuzz.